




RealRate

PHARMACEUTICAL 2023

Hepion Pharmaceuticals Inc
Rank 185 of 471



The relative strengths and weaknesses of Hepion Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hepion Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 92% points. The greatest weakness of Hepion Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 294%, being 50% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	56,496
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,886
Liabilities, Non-Current	0
Other Assets	3,667
Other Compr. Net Income	-90
Other Expenses	-1,003
Other Liabilities	2,503
Other Net Income	415
Other Revenues	0
Property and Equipment	82
Research and Development	33,269
Selling, General and Administrative Expense	10,348

Output Variable	Value in 1000 USD
Assets	60,244
Liabilities	10,389
Expenses	42,615
Revenues	0
Stockholders Equity	49,856
Net Income	-42,200
Comprehensive Net Income	-42,245
BaseVar	56,877
ECR before LimitedLiability	188%
Economic Capital Ratio	294%